Pfizer Inc. (PFE) is seeking emergency approval for its COVID-19 vaccine in India, according to media sources in the country.
What Happened
The vaccine developed together with BioNTech SE - ADR (BNTX) was approved in the U.K. last week. The pharmaceutical company has applied for approval with the Drugs Controller General of India, according to a Times of India report.
India has the second-highest number of infections, with more than 9.6 million cases. According to John Hopkins University, the U.S. has the highest number, at more than 14.5 million cases.
What’s Next
The vaccine would require to be stored at –70 degrees Celsius, which could present a huge challenge for India, the Times of India writes.
Price Action
Pfizer shares traded 0.025% lower at $40.33 in the postmarket session on Friday, December 4. BioNtech closed at $120 with a 1.11% gain on Friday's regular session.
Comments
Log in or sign up to join the conversation.